Metastatic Colorectal Cancer (mCRC)
Conditions
Keywords
mCRC, Checkmate-142, Nivolumab
Brief summary
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by: * Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x) * Pathology consistent with CRC * At least two documented clinical visits on or after January 1, 2013 * Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013 * Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR) * Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date * Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study
Exclusion criteria
* Participants \<18 years of age at index date * Participants who received clinical trial drug during the prior or post periods
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 6 years | — |
| Duration of Systemic Treatment | Up to 6 years | Durations were reported for the first line of therapy prior to the second line (2L) therapy of interest, the 2L therapy of interest, the third line of therapy, and the at least fourth line of therapy. |
Countries
United States
Outcome results
None listed